S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)

Lumos Pharma (LUMO) Competitors

$2.94
-0.08 (-2.65%)
(As of 02/23/2024 ET)

LUMO vs. FBRX, NRBO, VIRX, SLS, TXMD, APRE, DRRX, ACST, ALRN, and LSTA

Should you be buying Lumos Pharma stock or one of its competitors? The main competitors of Lumos Pharma include Forte Biosciences (FBRX), NeuroBo Pharmaceuticals (NRBO), Viracta Therapeutics (VIRX), SELLAS Life Sciences Group (SLS), TherapeuticsMD (TXMD), Aprea Therapeutics (APRE), DURECT (DRRX), Acasti Pharma (ACST), Aileron Therapeutics (ALRN), and Lisata Therapeutics (LSTA). These companies are all part of the "pharmaceutical preparations" industry.

Lumos Pharma vs.

Lumos Pharma (NASDAQ:LUMO) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, community ranking, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

In the previous week, Forte Biosciences had 1 more articles in the media than Lumos Pharma. MarketBeat recorded 2 mentions for Forte Biosciences and 1 mentions for Lumos Pharma. Forte Biosciences' average media sentiment score of 0.32 beat Lumos Pharma's score of 0.25 indicating that Forte Biosciences is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lumos Pharma
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Forte Biosciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Lumos Pharma has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500.

Forte Biosciences has a net margin of 0.00% compared to Lumos Pharma's net margin of -1,889.69%. Lumos Pharma's return on equity of -68.65% beat Forte Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Lumos Pharma-1,889.69% -68.65% -54.67%
Forte Biosciences N/A -88.96%-77.28%

Lumos Pharma received 9 more outperform votes than Forte Biosciences when rated by MarketBeat users. Likewise, 76.74% of users gave Lumos Pharma an outperform vote while only 55.81% of users gave Forte Biosciences an outperform vote.

CompanyUnderperformOutperform
Lumos PharmaOutperform Votes
33
76.74%
Underperform Votes
10
23.26%
Forte BiosciencesOutperform Votes
24
55.81%
Underperform Votes
19
44.19%

35.2% of Lumos Pharma shares are held by institutional investors. Comparatively, 94.2% of Forte Biosciences shares are held by institutional investors. 23.7% of Lumos Pharma shares are held by company insiders. Comparatively, 10.5% of Forte Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Lumos Pharma presently has a consensus target price of $18.00, suggesting a potential upside of 512.24%. Given Lumos Pharma's stronger consensus rating and higher probable upside, research analysts clearly believe Lumos Pharma is more favorable than Forte Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lumos Pharma
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Forte Biosciences
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Forte Biosciences has lower revenue, but higher earnings than Lumos Pharma. Lumos Pharma is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lumos Pharma$1.52M15.30-$31.06M-$4.00-0.74
Forte BiosciencesN/AN/A-$13.88M-$1.24-0.56

Summary

Lumos Pharma beats Forte Biosciences on 10 of the 17 factors compared between the two stocks.


Get Lumos Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for LUMO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LUMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LUMO vs. The Competition

MetricLumos PharmaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$23.26M$6.73B$5.04B$7.52B
Dividend YieldN/A2.72%2.88%3.86%
P/E Ratio-0.7418.60247.8418.81
Price / Sales15.30143.843,062.9055.11
Price / CashN/A18.1889.2952.42
Price / Book0.414.564.354.64
Net Income-$31.06M$158.17M$112.59M$207.29M
7 Day Performance-0.68%1.15%0.98%-1.00%
1 Month Performance2.44%10.76%6.98%3.28%
1 Year Performance-11.98%1.49%8.76%3.78%

Lumos Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FBRX
Forte Biosciences
2.2464 of 5 stars
$0.66
-2.9%
N/A-32.1%$24.00MN/A-0.539Options Volume
News Coverage
NRBO
NeuroBo Pharmaceuticals
0 of 5 stars
$4.93
-1.4%
N/A+12.0%$23.91MN/A0.002
VIRX
Viracta Therapeutics
2.0677 of 5 stars
$0.63
-3.1%
$7.75
+1,136.6%
-62.1%$24.20MN/A-0.5141Gap Up
SLS
SELLAS Life Sciences Group
1.3489 of 5 stars
$0.74
-6.3%
$3.00
+303.2%
-76.8%$23.86M$1M-0.4817News Coverage
TXMD
TherapeuticsMD
0 of 5 stars
$2.24
-0.4%
N/A-55.2%$23.70M$69.96M0.001
APRE
Aprea Therapeutics
2.6102 of 5 stars
$6.17
-3.6%
$14.50
+135.0%
+1.0%$23.08MN/A-1.559News Coverage
DRRX
DURECT
4.1729 of 5 stars
$0.84
-1.2%
$35.00
+4,066.7%
-80.8%$25.06M$19.28M-0.5372
ACST
Acasti Pharma
1.9229 of 5 stars
$2.45
-6.1%
$10.50
+328.6%
-1.7%$23.03M$200,000.00-0.4532News Coverage
ALRN
Aileron Therapeutics
2.3005 of 5 stars
$4.66
+7.4%
$9.00
+93.1%
+206.5%$22.79MN/A0.006Positive News
Gap Up
LSTA
Lisata Therapeutics
3.4559 of 5 stars
$2.76
+1.1%
$15.00
+444.5%
-9.9%$22.43MN/A-1.0327News Coverage
Positive News
Gap Down

Related Companies and Tools

This page (NASDAQ:LUMO) was last updated on 2/23/2024 by MarketBeat.com Staff